-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
[Promoting the Entrepreneurial Spirit: An Interview with a Renowned Hebei Entrepreneur] Bolstering Confidence in Corporate Development and Supporting the Building of a Healthy China—An Interview with Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical Co., Ltd.
Category:
发布时间：2020-07-25
【概要描述】
“General Secretary Xi Jinping’s important speech has bolstered the confidence of market entities and entrepreneurs, enabling them to focus wholeheartedly on development.” General Secretary Xi Jinping’s remarks at the symposium with entrepreneurs he chaired on July 21 have sparked an enthusiastic response at Shijiazhuang Sihua Pharmaceutical Co., Ltd. Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical, stated that the company will, in accordance with the General Secretary’s requirements, carry forward the spirit of entrepreneurship,
“General Secretary Xi Jinping’s important speech has bolstered the confidence of market entities and entrepreneurs, enabling them to focus wholeheartedly on development.” General Secretary Xi’s remarks at the symposium with entrepreneurs held on July 21 have sparked an enthusiastic response at Shijiazhuang Sihua Pharmaceutical Co., Ltd. Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical, stated that the company will heed the General Secretary’s call to carry forward the entrepreneurial spirit by continuously enhancing its commitment to patriotism, innovation, integrity, social responsibility, and a global outlook. The company will more consciously align its own future and destiny with those of the nation, shoulder the responsibility for national prosperity and the rejuvenation of the Chinese nation, and strive to contribute to the building of a Healthy China.
Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical
Innovation Never Stops, Catalyzing High-Quality Momentum
Shijiazhuang No.4 Pharmaceutical is a large-scale pharmaceutical enterprise in our province, primarily engaged in the production of chemical drugs, active pharmaceutical ingredients, and pharmaceutical packaging materials. It is also a leading Chinese company in the manufacturing, R&D, and export of large-volume parenteral solutions. In the recently released “Top 100 Chinese Pharmaceutical Companies” series of rankings on July 22, Shijiazhuang No.4 Pharmaceutical once again made the “Top 100 Chinese Chemical Pharmaceutical Enterprises” list, ranking 45th.
“In recent years, Shijiazhuang Sihua Pharmaceutical has achieved substantial progress in both its scale of operations and corporate performance, and a key factor behind this success is our unwavering commitment to innovation as the central driver of growth,” said Su Xuejun, Chairman of Shijiazhuang Sihua Pharmaceutical. He emphasized that steadfastly prioritizing innovation is a vital component of fostering the entrepreneurial spirit in the new era and is essential for strengthening the foundation and ensuring the long-term sustainability of the enterprise.
“Over the past several years, we have invested more than 5% of our sales revenue in innovation, successfully establishing high-level research and innovation platforms such as the National Enterprise Technology Center, the National–Local Joint Engineering Laboratory, and a Postdoctoral Research Station. We have also collaborated with renowned universities—including Zhejiang University, Tianjin University, and Zhengzhou University—to co-establish research centers, thereby forging a comprehensive, scientific, and well-defined technological innovation system. As a result, our capacity and level of technological innovation have steadily risen to the ranks of the ‘national team,’” said Su Xuejun. He emphasized that steadfastly pursuing an innovation-driven strategy is the fundamental cornerstone of the company’s growth and expansion.
Innovation is the primary driving force behind development. As a national high-tech enterprise, Shijiazhuang Sihua Pharmaceutical places great emphasis on R&D and human capital investment, effectively harnessing the creativity of its employees and striving to establish the company as a robust innovation leader. Currently, the Shijiazhuang Sihua Pharmaceutical Co., Ltd. Research Institute for Pharmaceutical Sciences boasts nearly 500 highly qualified professionals in drug research, analysis, clinical studies, and other specialized fields. The institute has established one of the most comprehensive R&D and innovation systems among domestic pharmaceutical companies, bringing together numerous innovative teams led by doctoral degree holders and leading experts, and undertaking multiple major national and provincial projects focused on technological innovation and industrialization.
Innovation entails courage—and, even more so, risk and challenge. With unwavering courage and bold vision in the face of adversity, Shijiazhuang Sihua Pharmaceutical has, after years of arduous effort, reached a remarkable moment of profound accumulation leading to breakthroughs. Today, the company launches more than 10 new products each year, has secured over 80 core proprietary intellectual property rights, and has more than 160 drug candidates in development, including several first-in-class innovations. “As General Secretary Xi Jinping has emphasized, the spirit of daring to lead the way is precisely the quality that must be vigorously promoted in order to overcome risks and challenges and achieve high-quality development,” said Su Xuejun.
Shijiazhuang Sihua Pharmaceutical Modernization Plant
Only through arduous effort can one truly savor the joy that comes with achievement. “Our portfolio of new products, led by injectable formulations, has been steadily expanding: since last year, we have obtained a total of 18 manufacturing approvals for generic drugs and two approvals for bioequivalence evaluations. Among these, tirofiban hydrochloride sodium chloride injection—a cardiovascular medication indicated for the treatment of acute coronary syndromes—demonstrates significant clinical potential and is poised to become a flagship product driving the company’s injectable business. The newly approved series of peritoneal dialysis solutions, when combined with our existing portfolio of peritoneal dialysis products, will help us enter the dialysis market and continuously expand our growth opportunities. Hydroxyethyl starch 130 sodium chloride injection is set to secure a strong foothold in the volume-expansion and anesthesia markets. In addition, three specifications of ambroxol ampoule injections will further enrich our respiratory product lineup. Furthermore, fluconazole tablets in both 50 mg and 150 mg strengths have passed bioequivalence evaluation, with the 150 mg formulation being the first of its kind in China to do so, which will unlock substantial market potential in future national tendering processes.” Su Xuejun spoke knowledgeably about the company’s research achievements.
Building the Enterprise on Credit: Strengthening the Foundation for Development
“The socialist market economy is a credit-based and rule-of-law-based economy.” General Secretary Xi Jinping succinctly encapsulated the essential characteristics of the socialist market economy at the symposium with entrepreneurs.
“A person cannot stand without integrity, and the same holds true for enterprises and entrepreneurs. To promote the entrepreneurial spirit, we must firmly instill a strong awareness of the rule of law, a commitment to the spirit of contract, and a steadfast adherence to contractual obligations—only then can we boldly lead the way in the torrent of the market economy and remain invincible.” Su Xuejun is deeply moved by the impact of the credit economy on enterprise development.
Su Xuejun stated that Shijiazhuang Sihua Pharmaceutical builds its enterprise on integrity, regarding honesty and trustworthiness as a key intangible asset for business operations and development. The company has enshrined “integrity as the foundation” as its corporate ethos and proactively upholds standardized contractual practices. Adhering to a “premium-quality strategy,” it has leveraged high-quality products and services to earn prestigious accolades such as the Hebei Provincial Government Quality Award, the China Enterprise Credit AAA Rating, the National Model Enterprise for Contract Compliance and Creditworthiness, and the Hebei Provincial Integrity Enterprise designation.
Strong corporate credit has enabled Shijiazhuang Sihua Pharmaceutical to enjoy smooth operations in overseas markets, establishing a “golden brand” in the eyes of international customers. To date, the company has obtained nearly 30 international certifications and undergone quality audits in multiple countries, with cumulative export sales spanning more than 90 countries and regions. It has also completed registration for over 200 product specifications, including ciprofloxacin lactate sodium chloride injection, metronidazole sodium chloride injection, sodium lactate Ringer’s injection, 18AA amino acid injection, and mannitol injection. In 2019, the company firmly held the top position among domestic intravenous solution manufacturers in terms of exports, maintaining double-digit growth for eight consecutive years.
Shijiazhuang Sihua Pharmaceutical’s world-class research facilities provide robust support and assurance for product development.
At a time when the COVID-19 pandemic is spreading globally, timely fulfillment of contracts and stable foreign trade demonstrate the sense of responsibility of a conscientious enterprise. Shijiazhuang Sihua Pharmaceutical has proactively responded to the impact of the pandemic, maintained unwavering focus on its international business, and ensured uninterrupted order fulfillment, continuous order intake, and seamless customer service through “screen-to-screen” and “line-to-line” communication. As a result, the company has earned the trust of its international clients and bolstered confidence in bilateral cooperation. In the first half of this year, both the volume of foreign-trade sales and export value have continued to grow steadily.
Upholding Our Original Aspiration and Mission, Sincerely Giving Back to Society
“To carry forward the entrepreneurial spirit, we must proactively shoulder national responsibilities, share the nation’s burdens, and fully fulfill our duty to serve the country,” said Su Xuejun.
During the COVID-19 pandemic, Shijiazhuang Sihua Pharmaceutical Co., Ltd. resolutely shouldered its social responsibility for epidemic prevention and control, demonstrating a strong sense of mission and commitment. The company mobilized its workforce to ensure the full-scale production of essential anti-pandemic medications, including Arbidol Hydrochloride Capsules, Moxifloxacin Hydrochloride Sodium Chloride Injection, and basic intravenous solutions. At the same time, it promptly organized the dispatch of emergency supplies to frontline medical teams in Hubei Province, thereby contributing the pharmaceutical industry’s strength to the overarching people’s war, all-out battle, and decisive campaign against the epidemic. Through these actions, the company has embodied the original aspiration and mission of pharmaceutical professionals.
During the pandemic, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. worked around the clock to produce the antiviral drug Arbidol capsules.
During this period, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. dispatched 3.962 million capsules of Arbidol to Hubei Province and 500,000 bags of epidemic-prevention medications, including moxifloxacin hydrochloride sodium chloride injection. The company also donated cash and materials totaling more than RMB 3 million to designated COVID-19 hospitals in Wuhan and the Shennongjia Forestry District, among other recipients. In addition, it provided 410,000 bottles (or barrels) of disinfectant to Beijing and Tianjin. The company successfully fulfilled national allocation and provincial-level procurement and stockpiling tasks, earning unanimous praise from the Medical Supplies Guarantee Group of the Joint Prevention and Control Mechanism under the State Council for Responding to the COVID-19 Epidemic, the Party Committee and government of the Shennongjia Forestry District, the Hubei Provincial Epidemic Command Center, and relevant medical institutions.
“As important market players in the socialist market economy, private enterprises should share the same destiny and common future with the nation’s development. We must closely align corporate growth with national prosperity, ethnic rejuvenation, and the well-being of the people, strive for high-quality enterprise development, and contribute to the building of a Healthy China,” said Su Xuejun.
(Originally published in “
Great Wall Network
》
)
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091